Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients
Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients
复制标题
DOI：
10.1038/sj.leu.2404270
复制
发表时间：
2006-08-01
期刊：
影响因子：
11.4
通讯作者：
Zheng, C.
中科院分区：
文献类型：
--
作者：
Frank, O.;Brors, B.;Zheng, C.
尽管选择性酪氨酸激酶抑制剂伊马替尼已成功用于治疗慢性粒细胞白血病（CML），但其固有机制赋予白血病患者主要耐药性。为了寻找预测细胞遗传学反应的潜在有用基因，进行了回顾性基因表达研究。在使用伊马替尼之前从经过干扰素 α 预处理的慢性期 CML 患者 (n = 34) 中分离出的白细胞 RNA，这些患者有或没有主要细胞遗传学缓解（
Although the selective tyrosine kinase inhibitor imatinib is successfully used in the treatment of chronic myeloid leukemia (CML), inherent mechanisms confer primary resistance to leukemic patients. In order to search for potentially useful genes in predicting cytogenetic response, a retrospective gene expression study was performed. Leukocyte RNA isolated before imatinib from interferon-alpha-pretreated chronic phase CML patients (n = 34) with or without major cytogenetic remission (